Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020
Stockholm, November 9, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today data on the drug candidate BAN2401 (lecanemab), which were presented by the ...
Press releases
BioArctic’s partner Eisai to present latest data on BAN2401 at CTAD conference
Stockholm, October 28, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will conduct four oral presentations related to ...
BioArctic winner of the Allbright Award 2020
Stockholm, October 15, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its ...
Interim Report for the period January – September 2020
An additional Phase 3 study in Alzheimer’s disease
BioArctic presents Nomination Committee
BioArctic presents Nomination Committee Stockholm, Sweden, October 13, 2020 – BioArctic's Annual General Meeting on May 7, 2020, adopted an instruction regarding the appointment of the Nomination ...
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2020 on October 14 at 9.30 a.m. CET
Stockholm, Sweden, October 6, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September 2020 on Wednesday, ...
Eisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020
Stockholm, July 30, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai presented the latest data from the open-label ...
BioArctic’s partner Eisai to present update on the development of BAN2401 at Alzheimer’s Association International Conference 2020
Stockholm, July 22, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will present the study design of the ...
New global Phase 3 program of BAN2401 initiated in preclinical (asymptomatic) Alzheimer’s disease
Stockholm, July 14, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its business partner Eisai, in collaboration with Alzheimer’s Clinical Trials Consortium ...
Interim Report for the period January – June 2020
Continued performance according to plan Key events during the second quarter 2020 BioArctic communicated that the mechanism of action for the AD1801 antibody project is ...
Invitation to presentation of BioArctic’s Interim Report for the period January – June 2020 on July 10 at 9.30 a.m. CET
Stockholm, Sweden, July 1, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June ...
BioArctic and University of Oslo sign research agreement to investigate Apolipoprotein E as a drug target for Alzheimer’s disease
Stockholm, Sweden, June 29, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and University of Oslo, Institute of Clinical Medicine (IKM), announced today that they ...
Members of BioArctic’s Board of Directors and management increase their shareholdings
Stockholm, Sweden, May 26, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that seven members of the company's Board and management today have ...
Report from Annual General Meeting in BioArctic (publ)
Stockholm, Sweden, May 7, 2020 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. The following resolutions were adopted. Adoption ...
Interim Report for the period January – March 2020
Operations performing according to plan Key events during the first quarter 2020 As of today, BioArctic has not experienced any noteworthy disruptions to its operations ...
Invitation to presentation of BioArctic’s Interim Report for the first quarter 2020 on April 22 at 9.30 a.m. CET
Stockholm, Sweden, April 15, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2020 ...
Notice of Annual General Meeting in BioArctic AB (Publ)
The Board of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday, 7 May 2020 More information about ...
BioArctic publishes the Annual Report for 2019
Stockholm April 2, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for the 2019 has been published in ...
The Nomination Committee’s proposal for the election of board members in BioArctic AB
Stockholm March 24, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Nomination Committee for BioArctic AB provides the following proposals for ...
Alzheimer patients at Swedish clinics to be included in Phase 3 study of drug candidate BAN2401
Stockholm, March 3, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will include Swedish clinics in the ...
Full Year Report for the period January – December 2019
Enhanced project portfolio from a successful year
Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2019 on February 6 at 9.30 a.m. CET
Stockholm, Sweden, January 28, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report for the period January – December ...
